% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Dzel:283041,
      author       = {Düzel, Emrah and Thyrian, Jochen René and Vossfeld,
                      Hannes and Berron, David and Jessen, Frank and Spottke,
                      Annika and Teipel, Stefan},
      title        = {{R}efer‐{MCI}: {E}nriching referrals of patients to
                      memory clinics for mild cognitive impairment ({MCI})},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {S3},
      issn         = {1552-5260},
      reportid     = {DZNE-2025-01448},
      pages        = {e106521},
      year         = {2025},
      abstract     = {Background: A timely diagnosis of mild cognitive impairment
                      (MCI) in Alzheimer’s disease (AD) is crucial for early
                      interventions, but its broad implementation in health-care
                      is often challenging due to the complexity and time burden
                      of required cognitive assessments. In the current German
                      health care system, less than $10\%$ of people with a
                      clinical syndrome of MCI are being identified in primary
                      care, even if specialists are included in the assessment. To
                      address these challenges, the usability of new unsupervised
                      digital remote assessment tools needs to be validated in a
                      routine care context. Method: The Refer-MCI study will
                      compare diagnosis and referral decisions basedon a remote
                      digital self-assessment (neotivCare app) with usual-care
                      based referral decision established in participating
                      office-based specialist care. The reference test willbe the
                      diagnosis of MCI due to AD at memory clinics according to S3
                      guidelines. All patients will also undergo an office-based
                      MoCA assessment. Blood-based biomarkersfor AD (pTau-217)
                      will be obtained at memory clinics. Result: N = 500
                      office-based care (N = 27 offices) patients, aged 60-80
                      years who seek advice for self-reported or carer-reported
                      cognitive complaints will be screened for participation,
                      $75\%$ (n = 400) are expected to consent. For all patients,
                      the office-based outpatient specialists will document their
                      diagnosis and referral decision prior to and following the
                      use of neotivCare. First patient in is expected in May 2025
                      and last patient out in February 2026. Conclusion: The goal
                      of Refer-MCI is to investigate the potential of digital
                      remote home-based assessment for improving efficient and
                      timely referral of patients who are likely to have MCI from
                      office-based specialized care to memory clinics. Refer-MCI
                      will assess whether remote digital self-assessment of
                      patients with memory complaints at office-based specialist
                      care can enrich referrals to memory clinics with MCI.
                      Refer-MCI will identify barriers for implementing tools for
                      efficient and timely referral of these patients. Established
                      memory clinic-based testing and blood-based biomarkers will
                      be used as reference standard to estimate the proportion of
                      MCI due AD among the referred patients.},
      month         = {Jul},
      date          = {2025-07-27},
      organization  = {Alzheimer’s Association
                       International Conference, Toronto
                       (Canada), 27 Jul 2025 - 31 Jul 2025},
      keywords     = {Humans / Cognitive Dysfunction: diagnosis / Aged /
                      Alzheimer Disease: diagnosis / Aged, 80 and over / Middle
                      Aged / Male / Female / Referral and Consultation /
                      Biomarkers: blood / Germany / Neuropsychological Tests /
                      Biomarkers (NLM Chemicals)},
      cin          = {AG Teipel / AG Düzel / AG Thyrian / AG Berron / AG Jessen
                      / AG Spottke},
      ddc          = {610},
      cid          = {I:(DE-2719)1510100 / I:(DE-2719)5000006 /
                      I:(DE-2719)1510800 / I:(DE-2719)5000070 / I:(DE-2719)1011102
                      / I:(DE-2719)1011103},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)1 / PUB:(DE-HGF)16},
      doi          = {10.1002/alz70857_106521},
      url          = {https://pub.dzne.de/record/283041},
}